Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J. Bellmunt J, et al. Among authors: trigo jm. Lancet Oncol. 2010 Apr;11(4):350-7. doi: 10.1016/S1470-2045(09)70383-3. Epub 2010 Feb 15. Lancet Oncol. 2010. PMID: 20163987 Clinical Trial.
Recommendations for the optimal management of early and advanced urothelial carcinoma.
Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JÁ, Bellmunt J. Castellano D, et al. Among authors: trigo jm. Cancer Treat Rev. 2012 Aug;38(5):431-41. doi: 10.1016/j.ctrv.2011.10.004. Epub 2011 Nov 23. Cancer Treat Rev. 2012. PMID: 22116017 Review.
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodríguez CA, Trigo JM, Vazquez J, Regueiro P, Dorado JF, Baselga J; Spanish Breast Cancer Cooperative Group SOLTI. Cortes J, et al. Among authors: trigo jm. Clin Cancer Res. 2009 Jan 1;15(1):307-14. doi: 10.1158/1078-0432.CCR-08-1113. Clin Cancer Res. 2009. PMID: 19118059 Clinical Trial.
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Felip E, et al. Among authors: trigo jm. Cancer Chemother Pharmacol. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. Epub 2022 Mar 17. Cancer Chemother Pharmacol. 2022. PMID: 35298698 Free PMC article. Clinical Trial.
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
Provencio M, Cobo M, Rodriguez-Abreu D, Calvo V, Carcereny E, Cantero A, Bernabé R, Benitez G, Castro RL, Massutí B, Del Barco E, García Campelo R, Guirado M, Camps C, Ortega AL, González Larriba JL, Sánchez A, Casal J, Sala MA, Juan-Vidal O, Bosch-Barrera J, Oramas J, Dómine M, Trigo JM, Blanco R, Calzas J, Morilla I, Padilla A, Pimentao J, Sousa PA, Torrente M. Provencio M, et al. Among authors: trigo jm. BMC Cancer. 2022 Jul 5;22(1):732. doi: 10.1186/s12885-022-09830-8. BMC Cancer. 2022. PMID: 35790916 Free PMC article.
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).
Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure Á, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J; Spanish Society of Medical Oncology. Colomer R, et al. Among authors: trigo jm. Ann Oncol. 2010 Feb;21(2):195-198. doi: 10.1093/annonc/mdp595. Ann Oncol. 2010. PMID: 20110291 Free PMC article. No abstract available.
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.
Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, Garcίa-Campelo R, González-Larriba JL, Sánchez-Torres JM, Isla D, Viñolas N, Camps C, Insa A, Juan Ó, Massuti B, Paredes A, Artal Á, López-Brea M, Palacios J, Felip E. Garrido P, et al. Among authors: trigo jm. Cancer Med. 2021 Sep;10(17):5878-5888. doi: 10.1002/cam4.4135. Epub 2021 Jul 23. Cancer Med. 2021. PMID: 34296539 Free PMC article. Clinical Trial.
141 results